# reload+after+2024-01-19 22:43:23.241479
address1§100 Fifth Avenue
city§Waltham
state§MA
zip§02451
country§United States
phone§617 977 5700
website§https://www.apellis.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
fullTimeEmployees§767
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Cedric  Francois M.D., Ph.D.', 'age': 51, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 1198613, 'exercisedValue': 2361171, 'unexercisedValue': 74089824}, {'maxAge': 1, 'name': 'Dr. Pascal  Deschatelets Ph.D.', 'age': 53, 'title': 'Co-Founder & Chief Scientific Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 688055, 'exercisedValue': 8370147, 'unexercisedValue': 37323160}, {'maxAge': 1, 'name': 'Mr. Alec  Machiels J.D., MBA', 'age': 50, 'title': 'Co-Founder & Director', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 72500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy E. Sullivan', 'age': 52, 'title': 'CFO & Treasurer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 716410, 'exercisedValue': 0, 'unexercisedValue': 19826460}, {'maxAge': 1, 'name': 'Mr. David O. Watson Esq., J.D.', 'age': 50, 'title': 'General Counsel', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 675349, 'exercisedValue': 0, 'unexercisedValue': 1272666}, {'maxAge': 1, 'name': 'Mr. Adam J. Townsend', 'age': 46, 'title': 'Chief Commercial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 701605, 'exercisedValue': 3198125, 'unexercisedValue': 11882916}, {'maxAge': 1, 'name': 'Ms. Nur  Nicholson', 'age': 54, 'title': 'Chief Technical Operations Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 373404, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James G. Chopas CPA', 'age': 57, 'title': 'VP, Corporate Controller & Chief Accounting Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Meredith  Kaya', 'title': 'Senior Vice President, Investor Relations & Strategic Finance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen  Lewis', 'age': 51, 'title': 'Chief People Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§6
compensationRisk§4
shareHolderRightsRisk§8
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.908
priceToSalesTrailing12Months§25.886333
currency§USD
dateShortInterest§1702598400
forwardEps§-1.7
pegRatio§-0.39
exchange§NMS
quoteType§EQUITY
shortName§Apellis Pharmaceuticals, Inc.
longName§Apellis Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1510237800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§0d6245e8-6d8f-3e7c-9153-78020c0f85eb
gmtOffSetMilliseconds§-18000000
targetHighPrice§95.0
targetLowPrice§39.0
targetMeanPrice§65.56
targetMedianPrice§67.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§16
quickRatio§3.515
grossMargins§0.85776
ebitdaMargins§-2.18032
trailingPegRatio§None
